Zhang, J., Cai, J., Wang, H., Yu, Y., Bosch-Barrera, J., Bernabé, R., Andric, Z., Badin, F. B., Okuma, Y., Paik, P. K., Naidoo, J., Kalofonos, H., Wang, B., Jotte, R. M., Pennell, N. A., Riess, J. W., Doroshow, D. B., Nishio, M., Alatorre-Alexander, J. A., Lu, S. (2025). A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8664